Overview

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma. PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Treatments:
Bleomycin
Carmustine
Cytarabine
Dacarbazine
Dexamethasone
Doxorubicin
Etoposide
Gemcitabine
Ifosfamide
Liposomal doxorubicin
Melphalan
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mitoguazone
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Vincristine
Vindesine
Vinorelbine